Polymorphism and Drug-Selected Mutations in the Protease Gene of Human Immunodeficiency Virus Type 2 from Patients Living in Southern France

Journal of Clinical Microbiology

Volumn 42, Issue 2, 2004, Pages 570-577

  Colson, P ^a   Henry, M ^a   Tourres, C ^a   Lozachmeur, D ^a   Gallais, H ^b   Gastaut, J A ^c   Moreau, J ^d   Tamalet, C ^a  

^a TIMONE HOSPITAL   (France)

^b HÔPITAL DE LA CONCEPTION   (France)

^c HÔPITAL SAINTE MARGUERITE   (France)

^d HÔPITAL NORD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

INDINAVIR; LOPINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; VIRUS DNA; VIRUS RNA;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; CLINICAL ARTICLE; CODON; DISEASE PREDISPOSITION; FEMALE; FRANCE; GENE FREQUENCY; GENE MUTATION; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC RESISTANCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONGITUDINAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; STRAIN IDENTIFICATION; VIRUS RESISTANCE; WILD TYPE;

ADULT; BASE SEQUENCE; CONSENSUS SEQUENCE; DNA PRIMERS; DNA, VIRAL; FEMALE; FRANCE; HIV INFECTIONS; HIV PROTEASE; HIV-2; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; SEXUAL BEHAVIOR;

DNA VIRUSES; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; RNA VIRUSES;

EID: 1242269308     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.42.2.570-577.2004     Document Type: Article

References (46)

1. Adjorlolo-Johnson, G., K. M. De Cock, E. Ekpini, K. M. Vetter, T. Sibailly, K. Brattegaard, D. Yavo, R. Doorly, J. P. Whitaker, and L. Kestens. 1994. Prospective comparison of mother-to-child transmission of HIV-1 and HIV-2 in Abidjan, Ivory Coast. JAMA 272:462-466.
2. Ancelle, R., O. Bletry, A. C. Baglin, F. Brun-Vezinet, M. A. Rey, and P. Godeau. 1987. Long incubation period for HIV-2 infection. Lancet i:688-689.
3. Andersson, S., H. Norrgren, Z. da Silva, A. Biague, S. Bamba, S. Kwok, C. Christopherson, G. Biberfeld, and J. Albert. 2000. Plasma viral load in HIV-1 and HIV-2 singly and dually infected individuals in Guinea-Bissau, West Africa: significantly lower plasma virus set point in HIV-2 infection than in HIV-1 infection. Arch. Intern. Med. 160:3286-3293.
4. Berry, N., K. Ariyoshi, S. Jaffar, S. Sabally, T. Corrah, R. Tedder, and H. Whittle. 1998. Low peripheral blood viral HIV-2 RNA in individuals with high CD4 percentage differentiates HIV-2 from HIV-1 infection. J. Hum. Virol. 1:457-468.
5. Bock, P. J., and D. M. Markovitz. 2001. Infection with HIV-2. AIDS 15: S35-S45.
6. Boden, D., and M. Markowitz. 1998. Resistance to human immunodeficiency virus type 1 protease inhibitors. Antimicrob. Agents Chemother. 42:2775-2783.
7. Bossi, P., M. Mouroux, A. Yvon, F. Bricaire, H. Agut, J. M. Huraux, C. Katlama, and V. Calvez. 1999. Polymorphism of the human immunodeficiency virus type 1 (HIV-1) protease gene and response of HIV-1-infected patients to a protease inhibitor. J. Clin. Microbiol. 37:2910-2912.
8. Chen, Z., A. Luckay, D. L. Sodora, P. Telfer, P. Reed, A. Gettie, J. M. Kanu, R. F. Sadek, J. Yee, D. D. Ho, L. Zhang, and P. A. Marx. 1997. Human immunodeficiency virus type 2 (HIV-2) seroprevalence and characterization of a distinct HIV-2 genetic subtype from the natural range of simian immunodeficiency virus-infected sooty mangabeys. J. Virol. 71:3953-3960.
9. Clavel, F. 1987. HIV-2, the West African AIDS virus. AIDS 1:135-140.
10. Clavel, F., D. Guetard, F. Brun-Vezinet, S. Chamaret, M. A. Rey, M. O. Santos-Ferreira, A. G. Laurent, C. Dauguet, C. Katlama, and C. Rouzioux. 1986. Isolation of a new human retrovirus from West African patients with AIDS. Science 233:343-346.
11. Damond, F., C. Apetrei, D. L. Robertson, S. Souquiere, A. Lepretre, S. Matheron, J. C. Plantier, F. Brun-Vezinet, and F. Simon. 2001. Variability of human immunodeficiency virus type 2 (HIV-2) infecting patients living in france. Virology 280:19-30.
12. Damond, F., M. Gueudin, S. Pueyo, I. Farfara, D. L. Robertson, D. Descamps, G. Chene, S. Matheron, P. Campa, F. Brun-Vezinet, and F. Simon. 2002. Plasma RNA viral load in human immunodeficiency virus type 2 subtype A and subtype B infections. J. Clin. Microbiol. 40:3654-3659.
13. De Cock, K. M., G. Adjorlolo, E. Ekpini, T. Sibailly, J. Kouadio, M. Maran, K. Brattegaard, K. M. Vetter, R. Doorly, and H. D. Gayle. 1993. Epidemiology and transmission of HIV-2. Why there is no HIV-2 pandemic. JAMA 270:2083-2086.
14. Descamps, D., G. Collin, F. Letourneur, C. Apetrei, F. Damond, I. Loussert-Ajaka, F. Simon, S. Saragosti, and F. Brun-Vezinet. 1997. Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analyses. J. Virol. 71:8893-8898.
15. Fan, N., K. B. Rank, J. W. Leone, R. L. Heinrikson, C. A. Bannow, C. W. Smith, D. B. Evans, S. M. Poppe, W. G. Tarpley, and D. J. Rothrock. 1995. The differential processing of homodimers of reverse transcriptases from human immunodeficiency viruses type 1 and 2 is a consequence of the distinct specificities of the viral proteases. J. Biol. Chem. 270:13573-13579.
16. Frater, J., D. Dunn, J. N. Weber, and M. O. McClure. 2002. Association between secondary mutations in human immunodeficiency virus type 1 protease and therapeutic outcome. J. Infect. Dis. 185:1376.
17. Gao, F., L. Yue, D. L. Robertson, S. C. Hill, H. Hui, R. J. Biggar, A. E. Neequaye, T. M. Whelan, D. D. Ho, and G. M. Shaw. 1994. Genetic diversity of human immunodeficiency virus type 2: evidence for distinct sequence subtypes with differences in virus biology. J. Virol. 68:7433-7447.
18. Ghys, P. D., K. Fransen, M. O. Diallo, V. Ettiegne-Traore, I. M. Coulibaly, K. M. Yeboue, M. L. Kalish, C. Maurice, J. P. Whitaker, A. E. Greenberg, and M. Laga. 1997. The associations between cervicovaginal HIV shedding, sexually transmitted diseases and immunosuppression in female sex workers in Abidjan, Cote d'Ivoire. AIDS 11:F85-F93.
19. Kanki, P. 1991. Biological features of HIV-2. An update. AIDS Clin. Rev. 1991:17-38.
20. Kozal, M. J., N. Shah, N. Shen, R. Yang, R. Fucini, T. C. Merigan, D. D. Richman, D. Morris, E. Hubbell, M. Chee, and T. R. Gingeras. 1996. Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nat. Med. 2:753-759.
21. Kuiken, C., B. Foley, B. Hahn, P. Marx, F. McCutchan, J. Mellors, S. Wolinsky, and B. Korber (ed.). HIV sequence compendium 2001. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, N.M.
22. Langley, C. L., E. Benga-De, C. W. Critchlow, I. Ndoye, M. D. Mbengue-Ly, J. Kuypers, G. Woto-Gaye, S. Mboup, C. Bergeron, K. K. Holmes, and N. B. Kiviat. 1996. HIV-1, HIV-2, human papillomavirus infection and cervical neoplasia in high-risk African women. AIDS 10:413-417.
23. Marlink, R. 1996. Lessons from the second AIDS virus, HIV-2. AIDS 10:689-699.
24. Marlink, R., P. Kanki, I. Thior, K. Travers, G. Eisen, T. Siby, I. Traore, C. C. Hsieh, M. C. Dia, and E. H. Gueye. 1994. Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science 265:1587-1590.
25. Palella, F. J., Jr., K. M. Delaney, A. C. Moorman, M. O. Loveless, J. Fuhrer, G. A. Satten, D. J. Aschman, S. D. Holmberg, and HIV Outpatient Study Investigators. 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 338:853-860.
26. Peeters, M. 2001. The genetic variability of HIV-1 and its implications. Transfus. Clin. Biol. 8:222-225.
27. Peeters, M., B. Koumare, C. Mulanga, C. Brengues, B. Mounirou, F. Bougoudogo, S. Ravel, F. Bibollet-Ruche, and E. Delaporte. 1998. Genetic subtypes of HIV type 1 and HIV type 2 strains in commercial sex workers from Bamako, Mali. AIDS Res. Hum. Retroviruses 14:51-58.
28. Perno, C. F., A. Cozzi-Lepri, C. Balotta, F. Forbici, M. Violin, A. Bertoli, G. Facchi, P. Pezzotti, G. Cadeo, G. Tositti, S. Pasquinucci, S. Pauluzzi, A. Scalzini, B. Salassa, A. Vincenti, A. N. Phillips, F. Dianzani, A. Appice, G. Angarano, L. Monno, G. Ippolito, M. Moroni, and A. d' Arminio Monforte. 2001. Secondary mutations in the protease region of human immunodeficiency virus and virologic failure in drug-naive patients treated with protease inhibitor-based therapy. J. Infect. Dis. 184:983-991.
29. Phylip, L. H., A. D. Richards, J. Kay, J. Kovalinka, P. Strop, I. Blaha, J. Velek, V. Kostka, A. J. Ritchie, and A. V. Broadhurst. 1990. Hydrolysis of synthetic chromogenic substrates by HIV-1 and HIV-2 proteinases. Biochem. Biophys. Res. Commun. 171:439-444.
30. Popper, S. J., A. D. Sarr, K. U. Travers, A. Gueye-Ndiaye, S. Mboup, M. E. Essex, and P. J. Kanki. 1999. Lower human immunodeficiency virus (HIV) type 2 viral load reflects the difference in pathogenicity of HIV-1 and HIV-2. J. Infect. Dis. 180:1116-1121.
31. Poulsen, A. G., B. Kvinesdal, P. Aaby, K. Molbak, K. Frederiksen, F. Dias, and E. Lauritzen. 1989. Prevalence of and mortality from human immunodeficiency virus type 2 in Bissau, West Africa. Lancet i:827-831.
32. Priestle, J. P., A. Fassler, J. Rosel, M. Tintelnot-Blomley, P. Strop, and M. G. Grutter. 1995. Comparative analysis of the X-ray structures of HIV-1 and HIV-2 proteases in complex with CGP 53820, a novel pseudosymmetric inhibitor. Structure 3:381-389.
33. Ren, J., L. E. Bird, P. P. Chamberlain, G. B. Stewart-Jones, D. I. Stuart, and D. K. Stammers. 2002. Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to non-nucleoside inhibitors. Proc. Natl. Acad. Sci. USA 99:14410-14415.
34. Rodes, B., A. Holguin, V. Soriano, M. Dourana, K. Mansinho, F. Antunes, and J. Gonzalez-Lahoz. 2000. Emergence of drug resistance mutations in human immunodeficiency virus type 2-infected subjects undergoing antiretroviral therapy. J. Clin. Microbiol. 38:1370-1374.
35. Simon, F., S. Matheron, C. Tamalet, I. Loussert-Ajaka, S. Bartczak, J. M. Pepin, C. Dhiver, E. Gamba, C. Elbim, and J. A. Gastaut. 1993. Cellular and plasma viral load in patients infected with HIV-2. AIDS 7:1411-1417.
36. Soriano, V., P. Gomes, W. Heneine, A. Holguin, M. Doruana, R. Antunes, K. Mansinho, W. M. Switzer, C. Araujo, V. Shanmugam, H. Lourenco, J. Gonzalez-Lahoz, and F. Antunes. 2000. Human immunodeficiency virus type 2 (HIV-2) in Portugal: clinical spectrum, circulating subtypes, virus isolation, and plasma viral load. J. Med. Virol. 61:111-116.
37. Switzer, W. M., S. Wiktor, V. Soriano, A. Silva-Graca, K. Mansinho, I. M. Coulibaly, E. Ekpini, A. E. Greenberg, T. M. Folks, and W. Heneine. 1998. Evidence of Nef truncation in human immunodeficiency virus type 2 infection. J. Infect. Dis. 177:65-71.
38. Takehisa, J., M. Osei-Kwasi, N. K. Ayisi, O. Hishida, T. Miura, T. Igarashi, J. Brandful, W. Ampofo, V. B. Netty, M. Mensab, M. Yamashita, E. Ido, and M. Hayami. 1997. Phylogenetic analysis of HIV type 2 in Ghana and intra-subtype recombination in HIV type 2. AIDS Res. Hum. Retroviruses 13:621-623.
39. Thompson, J. D., T. J. Gibson, F. Plewniak, F. Jeanmougin, and D. G. Higgins. 1997. The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res. 25:4876-4882.
40. Tomasselli, A. G., J. O. Hui, T. K. Sawyer, D. J. Staples, C. Bannow, I. M. Reardon, W. J. Howe, D. L. DeCamp, C. S. Craik, and R. L. Heinrikson. 1990. Specificity and inhibition of proteases from human immunodeficiency viruses 1 and 2. J. Biol. Chem. 265:14675-14683.
41. Vacca, J. P., B. D. Dorsey, W. A. Schleif, R. B. Levin, S. L. McDaniel, P. L. Darke, J. Zugay, J. C. Quintero, O. M. Blahy, and E. Roth. 1994. L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc. Natl. Acad. Sci. USA 91:4096-4100.
42. Vittinghoff, E., S. Scheer, P. O'Malley, G. Colfax, S. D. Holmberg, and S. P. Buchbinder. 1999. Combination antiretroviral therapy and recent declines in AIDS incidence and mortality. J. Infect. Dis. 179:717-720.
43. Weber, J., P. Majer, J. Litera, J. Urban, M. Soucek, J. Vondrasek, J. Konvalinka, P. Novek, J. Sedlacek, P. Strop, H. G. Krausslich, and I. Pichova. 1997. Potency comparison of peptidomimetic inhibitors against HIV-1 and HIV-2 proteinases: design of equipotent lead compounds. Arch. Biochem. Biophys. 341:62-69.
44. Whittle, H., A. Egboga, J. Todd, T. Corrah, A. Wilkins, E. Demba, G. Morgan, M. Rolfe, N. Berry, and R. Tedder. 1992. Clinical and laboratory predictors of survival in Gambian patients with symptomatic HIV-1 or HIV-2 infection. AIDS 6:685-689.
45. Wilkins, A., D. Ricard, J. Todd, H. Whittle, F. Dias, and A. Paulo Da Silva. 1993. The epidemiology of HIV infection in a rural area of Guinea-Bissau. AIDS 7:1119-1122.
46. Yamaguchi, J., S. G. Devare, and C. A. Brennan. 2000. Identification of a new HIV-2 subtype based on phylogenetic analysis of full-length genomic sequence. AIDS Res. Hum. Retroviruses 16:925-930.